Nov 08, 2019 7:00am EST Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments
Oct 29, 2019 7:00am EDT Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
Oct 16, 2019 4:35pm EDT Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 08, 2019 7:00am EDT Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Sep 04, 2019 7:00am EDT Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
Aug 14, 2019 6:15am EDT Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments
Jun 15, 2019 6:00am EDT Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
